This HTML5 document contains 125 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1590/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q90298472
rdf:type
wikibase:Item
schema:description
บทความทางวิทยาศาสตร์ 2020年の論文 scientific article published on 01 May 2020 2020年學術文章 vitskapeleg artikkel 2020 nî lūn-bûn 2020年学术文章 научна статия articolo scientifico artikel ilmiah মে ২০২০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ article scientifique artigo científico 2020년 논문 tieteellinen artikkeli научни чланак wetenschappelijk artikel vetenskaplig artikel scientific article published in May 2020 2020年学术文章 bài báo khoa học artículu científicu artikulong pang-agham 2020年學術文章 מאמר מדעי 2020年學術文章 naučni članak artículo científico publicado en 2020 مقالة علمية نشرت في مايو 2020 2020年学术文章 scienca artikolo мақолаи илмӣ teaduslik artikkel artigo científico article scientific επιστημονικό άρθρο наукова стаття, опублікована в травні 2020 bilimsel makale scientific article published in May 2020 vedecký článok 2020年学术文章 articol științific 2020年学术文章 tudományos cikk 2020年學術文章 artykuł naukowy artikull shkencor научная статья 2020年學術文章 სამეცნიერო სტატია article científic videnskabelig artikel udgivet maj 2020 wissenschaftlicher Artikel vitenskapelig artikkel vědecký článek научни чланак artigo científico 2020年学术文章
p:P577
wds:Q90298472-B1653270-A809-4B6E-899D-64EA23235F02
wdt:P577
2020-05-01T00:00:00Z
p:P2860
wds:Q90298472-EC874F1D-5F16-4518-83B0-58A380C7C495 wds:Q90298472-F19FB57E-985B-4AE4-B06E-A635EEE300D5 wds:Q90298472-FD98D2EF-13EF-487A-905B-B498EC3C98F0 wds:Q90298472-C5AAA6F1-7E72-4EAC-B2DF-C2E03E82CAE6 wds:Q90298472-C5D5E847-9A21-4785-AD54-4A0DC9D6C67B wds:Q90298472-C8B0E06F-3C5A-46A7-B448-F7082439450A wds:Q90298472-D19D6D59-5725-4BD8-9EE0-3F123736B078 wds:Q90298472-6752D60B-6D70-498A-A457-CD0FFE9A63F5 wds:Q90298472-6BE36980-80AF-4142-B4CC-B3BAB701D445 wds:Q90298472-914A81B6-F66F-46DC-9D83-70BF0A9D1ACF wds:Q90298472-9A3D8C2B-770A-4BF1-811B-BEC442DE3057 wds:Q90298472-1B0A9BAE-D589-43FA-B4B0-84C374FB6AA9 wds:Q90298472-28B34FBC-9D28-431D-A6CC-74868FEE2B67 wds:Q90298472-3B10533C-48A4-476B-B8D2-A4A98B1EB275 wds:Q90298472-48AB0697-76BC-4F30-ACE6-6FC5D125E423 wds:Q90298472-501A8C0F-9A1F-4DEE-98F3-133C78040F07
wdt:P2860
wd:Q33975462 wd:Q59289722 wd:Q46890166 wd:Q50427826 wd:Q82249836 wd:Q47379570 wd:Q38652111 wd:Q38935652 wd:Q42949896 wd:Q41864598 wd:Q57106013 wd:Q36975113 wd:Q27861047 wd:Q44108671 wd:Q59807267 wd:Q28071795
p:P2093
wds:Q90298472-202E8E42-AADC-4A1C-B9C8-03E6612DBF38 wds:Q90298472-567A5983-14EE-4476-BA6F-D6232FFB21C4
wdt:P2093
Carla S M de Freitas Aleida N Soares
rdfs:label
Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer
skos:prefLabel
Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer
schema:name
Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer
p:P1476
wds:Q90298472-A321CAE0-7F5D-44F3-B84D-596EAE3FFC56
wdt:P1476
Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer
p:P304
wds:Q90298472-C27BD6FB-CAC1-4E06-A51C-BFAACC46EE26
wdt:P304
383-389
p:P31
wds:Q90298472-ABCABC55-5EA1-4E26-9875-D195852DF409
wdt:P31
wd:Q13442814
p:P921
wds:Q90298472-54F7FA6F-4CC5-466C-AB17-574DE194D132
wdt:P921
wd:Q155
p:P698
wds:Q90298472-E61856C0-516C-48D6-AE52-08C4CA55D6AF
wdtn:P698
n9:32167701
wdt:P698
32167701
p:P1433
wds:Q90298472-ECD05349-856C-41C2-9A82-7D470888C959
wdt:P1433
wd:Q26841933
p:P433
wds:Q90298472-87CAED4A-269E-44CF-A155-06D17E4F9C1B
p:P478
wds:Q90298472-12521E59-C039-4B30-974C-7A7D81C21B09
wdt:P433
3
wdt:P478
46
p:P356
wds:Q90298472-74ED597B-088D-4719-AF87-7E87178BA317
wdtn:P356
n10:S1677-5538.IBJU.2019.0212
wdt:P356
10.1590/S1677-5538.IBJU.2019.0212
p:P932
wds:Q90298472-380EECCE-A70A-479E-9D58-E03A33A29CAB
wdt:P932
7088496